GlassScriptPhysician profile
Alan Goldberg
NPI 1538149844
$3,119.46
in general payments reported to CMS, 2019-2025
31 companies · $349 in 2025
The $349 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $444 · 2020: $479 · 2021: $820 · 2022: $556 · 2023: $133 · 2024: $338 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $819.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $625.02 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $328.98 | 2019-2025 | |
| Lilly USA, LLC | $211.16 | 2019-2025 | Jardiance, Trulicity, Mounjaro |
| Sanofi-Aventis U.S. LLC | $204.71 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $176.88 | 2019-2025 | |
| Astellas Pharma US INC | $157.65 | 2019-2024 | Veozah |
| Mannkind Corporation | $141.73 | 2022 | |
| Pfizer INC. | $132.35 | 2019-2024 | |
| Abbott Laboratories | $122.53 | 2022-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $119.29 | 2020-2024 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $117.26 | 2019-2025 | Breztri |
| Merck Sharp & Dohme LLC | $97.15 | 2019-2021 | |
| Dexcom, INC. | $94.76 | 2021-2022 | |
| Hologic Sales and Service, LLC | $69.91 | 2019 | |
| Allergan, INC. | $63.70 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.52 | 2019-2025 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $56.63 | 2021 | |
| Philips North America LLC | $52.48 | 2021-2022 | |
| Daiichi Sankyo INC. | $35.01 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.53 | 2022 | |
| Amgen INC. | $33.56 | 2021 | |
| Amarin Pharma, INC. | $27.50 | 2021 | |
| Sun Pharmaceutical Industries INC. | $27.16 | 2021 | |
| Janssen Pharmaceuticals, INC | $20.38 | 2020 | |
| Medtronic, INC. | $16.25 | 2025 | Minimed 780g |
| Exact Sciences Corporation | $16.13 | 2024 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $15.51 | 2023 | |
| Verrica Pharmaceuticals INC. | $15.03 | 2024 | Ycanth |
| Genentech USA, INC. | $14.98 | 2019 | |
| Collegium Pharmaceutical, INC. | $14.39 | 2025 | Jornay Pm |
| Shire North American Group INC | $14.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Goldberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.